BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 29498921)

  • 41. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma.
    Bastos AU; Oler G; Nozima BH; Moysés RA; Cerutti JM
    Eur J Endocrinol; 2015 Oct; 173(4):525-40. PubMed ID: 26338373
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High expression and localization of β-catenin and epidermal growth factor receptor identify high risk papillary thyroid carcinoma patients.
    Išić Denčić T; Bartolome A; Šelemetjev S; Đorić I; Tatić S; Živaljević V; Cvejić D
    Exp Mol Pathol; 2018 Oct; 105(2):181-189. PubMed ID: 30077672
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preserved SCN4B expression is an independent indicator of favorable recurrence-free survival in classical papillary thyroid cancer.
    Gong Y; Yang J; Wu W; Liu F; Su A; Li Z; Zhu J; Wei T
    PLoS One; 2018; 13(5):e0197007. PubMed ID: 29723302
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma.
    Ulisse S; Baldini E; Sorrenti S; Barollo S; Gnessi L; Catania A; Pellizzo MR; Nardi F; Mian C; De Antoni E; D'Armiento M; Frati L
    J Clin Endocrinol Metab; 2011 Feb; 96(2):504-8. PubMed ID: 21106716
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High recurrent rate of multicentric papillary thyroid carcinoma.
    Lin JD; Chao TC; Hsueh C; Kuo SF
    Ann Surg Oncol; 2009 Sep; 16(9):2609-16. PubMed ID: 19533244
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pediatric patients with multifocal papillary thyroid cancer have higher recurrence rates than adult patients: a retrospective analysis of a large pediatric thyroid cancer cohort over 33 years.
    Lee YA; Jung HW; Kim HY; Choi H; Kim HY; Hah JH; Park DJ; Chung JK; Yang SW; Shin CH; Park YJ
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1619-29. PubMed ID: 25632969
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Low-Activity Radioactive Iodine Therapy for Thyroid Carcinomas Exhibiting Nodal Metastases and Extrathyroidal Extension May Lead to Early Disease Recurrence.
    Chu KP; Baker S; Zenke J; Morad A; Ghosh S; Morrish DW; McEwan AJBS; Williams DC; Severin D; McMullen TPW
    Thyroid; 2018 Jul; 28(7):902-912. PubMed ID: 29742993
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Clinicopathologic and molecular features of cribriform morular variant of papillary thyroid carcinoma].
    Cui XJ; Zhao HO; Su P; Chen J; Zhang RY; Pan Y; Ouyang XM; Liu J; Zhang JQ; Yang Y; Yang R; Ding L; Liu ZY
    Zhonghua Bing Li Xue Za Zhi; 2018 May; 47(5):354-359. PubMed ID: 29783802
    [No Abstract]   [Full Text] [Related]  

  • 49. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
    Chowdhury S; Veyhl J; Jessa F; Polyakova O; Alenzi A; MacMillan C; Ralhan R; Walfish PG
    Oncotarget; 2016 May; 7(22):32318-28. PubMed ID: 27086918
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association between the HLA-G molecule and lymph node metastasis in papillary thyroid cancer.
    Nunes LM; Ayres FM; Francescantonio IC; Saddi VA; Avelino MA; Alencar Rde C; Silva RC; Meneghini AJ; Wastowski IJ
    Hum Immunol; 2013 Apr; 74(4):447-51. PubMed ID: 23261411
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic variables of papillary thyroid carcinomas with local invasion.
    Lin JD; Chao TC; Weng HF; Ho YS
    Endocr J; 1999 Feb; 46(1):91-8. PubMed ID: 10426572
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
    Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
    Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Expression of leptin and its receptor in thyroid carcinoma: distinctive prognostic significance in different subtypes.
    Fan YL; Li XQ
    Clin Endocrinol (Oxf); 2015 Aug; 83(2):261-7. PubMed ID: 25158596
    [TBL] [Abstract][Full Text] [Related]  

  • 54. LGR5 is associated with tumor aggressiveness in papillary thyroid cancer.
    Michelotti G; Jiang X; Sosa JA; Diehl AM; Henderson BB
    Oncotarget; 2015 Oct; 6(33):34549-60. PubMed ID: 26416247
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic significance of extranodal extension of regional lymph node metastasis in papillary thyroid cancer.
    Wu MH; Shen WT; Gosnell J; Duh QY
    Head Neck; 2015 Sep; 37(9):1336-43. PubMed ID: 24821456
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical features and prognostic factors for survival in patients with poorly differentiated thyroid carcinoma and comparison to the patients with the aggressive variants of papillary thyroid carcinoma.
    Jung TS; Kim TY; Kim KW; Oh YL; Park DJ; Cho BY; Shong YK; Kim WB; Park YJ; Jung JH; Chung JH
    Endocr J; 2007 Apr; 54(2):265-74. PubMed ID: 17379963
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MicroRNA-451 as a prognostic marker for diagnosis and lymph node metastasis of papillary thyroid carcinoma.
    Zhang M; Wu W; Gao M; Fei Z
    Cancer Biomark; 2017 Jul; 19(4):437-445. PubMed ID: 28582849
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Contralateral papillary thyroid cancer at completion thyroidectomy has no impact on recurrence or survival after radioiodine treatment.
    Grigsby PW; Reddy RM; Moley JF; Hall BL
    Surgery; 2006 Dec; 140(6):1043-7; discussion 1047-9. PubMed ID: 17188155
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Loss of cellular polarity/cohesiveness in the invasive front of papillary thyroid carcinoma, a novel predictor for lymph node metastasis; possible morphological indicator of epithelial mesenchymal transition.
    Liu Z; Kakudo K; Bai Y; Li Y; Ozaki T; Miyauchi A; Taniguchi E; Mori I
    J Clin Pathol; 2011 Apr; 64(4):325-9. PubMed ID: 21296795
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of evidence-based guidelines reduces radioactive iodine treatment in patients with low-risk differentiated thyroid cancer.
    Sacks W; Wong RM; Bresee C; Braunstein GD
    Thyroid; 2015 Apr; 25(4):377-85. PubMed ID: 25578116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.